Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Tocilizumab (a Monoclonal Antibody to Receptor of IL-6) in the Treatment of Adult's Still Disease

NCT01002781 is registered in ClinicalTrials.gov with Tel-Aviv Sourasky Medical Center as lead sponsor.

NCT NCT01002781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01002781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Tocilizumab (a Monoclonal Antibody to Receptor of IL-6) in the Treatment of Adult's Still Disease
Lead sponsor
Tel-Aviv Sourasky Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2009
Completion date
July 31, 2011
Enrollment
10 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adult's still disease